期刊文献+

利用丙型肝炎病毒复制子模型检测重组人λ2干扰素的体外活性

Detection of Interferon λ2 Activity In Vitro by HCV Replicon Model
下载PDF
导出
摘要 目的:利用丙型肝炎病毒(HCV)复制子细胞模型,体外研究重组人λ2干扰素(hIFNλ2)对HCV复制子的抑制作用。方法:构建重组质粒pcDNA3.1-hIFNλ2-HA,转染293T细胞,表达带有HA标签的hIFNλ2,表达后的上清通过Western印迹检测,然后稀释至不同浓度后作用于带有HCV复制子的Huh7.5细胞系,每隔24h取样并更换培养液,通过报告基因检测hIFNλ2对HCV复制子的抑制作用。结果:构建了pcDNA3.1-hIFNλ2-HA真核表达重组体,并在293T细胞中表达出hIFNλ2,该蛋白能有效抑制HCV复制子的复制。结论:hIFNλ2对HCV复制子具有抑制作用。 Objective:To study the inhibitory effect of recombinant human interferonλ2(hIFNλ2)on HCV replicon in vitro by using cell culture system of HCV replicon.Methods:This study constructed recombinant plasmidpcDNA3.1-hIFNλ2-HA,and expressed the hIFNλ2with HA tag in293T cells,then detected the supernatant ofthe cell by Western blot,and then used supernatant diluted with different ratio to effect on Huh7.5cell culturesystem with HCV replicon,samples were collected every24hours and replaced the medium,finally using the report gene to detect the inhibitory effect of the hIFNλ2in HCV virus replicon.Results:The eukaryotic expressionrecombinant plasmid pcDNA3.1-hIFNλ2was successfully contructed,and hIFNλ2was expressed in293T cells,and confirmed that the hIFNλ2could inhibit the replication of HCV.Conclusion:The results proved that hIFNλ2has a direct inhibitory effect on HCV replicon.
作者 张辉 李亚东 毕研伟 宫悦 李智华 丁晨 寸韡 ZHANG Hui;LI Ya-Dong;BI Yan-Wei;GONG Yue;LI Zhi-Hua;DING Chen;CUN Wei(Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming 650118,China;Yunnan Key Laboratory of Vaccine Research and Development of Severe Infectious Disease, Kunming 650118, China)
出处 《生物技术通讯》 CAS 2017年第5期595-599,633,共6页 Letters in Biotechnology
基金 云南省重点新产品开发计划(2015BC010)
关键词 重组人λ2干扰素 抑制 HCV复制子 recombinant human interferon λ2 inhibition HCV replicon
  • 相关文献

参考文献2

二级参考文献28

  • 1刘畅,乔文涛,王琛,耿运琪.类泛素蛋白ISG 15及其在先天免疫中的作用[J].生物化学与生物物理进展,2006,33(11):1023-1029. 被引量:10
  • 2Robertson B, Myers G, Howard C, et al. Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. International Committee on Virus Taxonomy. Arch Virol, 1998, 143 ( 12 ) : 2493-2503.
  • 3Sklan EH, Charuworn P, Pang PS, et al. Mechanisms of HCV survival in the host. Nat Bev Gastroenterol Hepatol, 2009, 6(4) : 217-227.
  • 4Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med, 2001, 345(1): 41-52.
  • 5Kuo G, Choo QL, Alter HJ, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science, 1989, 244(4902) : 362-364.
  • 6Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2h plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet, 2001,358(9286) : 958-965.
  • 7Lohmann V, Komer F, Koch J, et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science, 1999, 285(5424) : 110-113.
  • 8Kato T, Date T, Miyamoto M, et al. Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenterology, 2003, 125(6) : 1808-1817.
  • 9Cai Z, Zhang C, Chang KS, et al. Robust production of infectious hepatitis C virus (HCV) from stably HCV cDNA-transfected human hepatoma cells. J Virol, 2005, 79(22) : 13963-13973.
  • 10Lindenbach BD, Evans M J, Syder A J, et al. Complete replication of hepatitis C virus in cell culture. Science, 2005, 309 (5734) : 623-626.

共引文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部